Advaxis, Inc. (ADXS)
-OTC BB 0.05 
0.00(2.94%) May 17, 3:59PM EDT
| Prev Close: | 0.05 |
|---|
| Open: | 0.05 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 0.50 |
|---|
| Beta: | 1.56 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.05 - 0.06 |
|---|
| 52wk Range: | 0.03 - 0.16 |
|---|
| Volume: | 1,525,226 |
|---|
| Avg Vol (3m): | 2,481,720 |
|---|
| Market Cap: | 26.56M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.04 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ADVAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial ObligatiEDGAR Online(Wed, May 8)
- Advaxis Announces 2013 Annual Meeting of StockholdersBusiness Wire(Mon, May 6)
- Advaxis Announces Promotion of Dr. Robert Petit and Daniel J. O’ConnorBusiness Wire(Mon, May 6)
- Advaxis Reports Encouraging Preliminary Data from Penn Phase 1 ADXS-cHER2 Canine Osteosarcoma StudyBusiness Wire(Mon, Apr 29)
- Advaxis Announces First Patient Dosed in Brown University Sponsored Anal Cancer StudyBusiness Wire(Mon, Apr 22)
- Advaxis and FusionVax Sign a Memorandum of Understanding for the License of Advaxis’ ADXS-HPV in AsiaBusiness Wire(Mon, Apr 22)
- Advaxis to Present at the BIO International ConventionBusiness Wire(Thu, Apr 18)
- Advaxis to Report 12-Month Survival from Its Phase 2 Study of ADXS-HPV in Women with Recurrent/Refractory Cervical CancerBusiness Wire(Wed, Apr 17)
- ADVAXIS, INC. FinancialsEDGAR Online Financials(Fri, Mar 29)
- Advaxis Announces Abstract Accepted for Oral Presentation at SITC Cancer Immunotherapy Clinical Trials WorkshopBusiness Wire(Tue, Mar 26)
- ADVAXIS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, Mar 25)
- Advaxis Nominated for Best Early-Stage Vaccine Biotech at 6th Annual Vaccine Industry Excellence AwardsBusiness Wire(Wed, Mar 13)
- University of Pennsylvania Researchers Receive Penn One Health Award for Research Initiatives in Canine Osteosarcoma with Advaxis’ ADXS-cHER2 ImmunotherapyBusiness Wire(Mon, Mar 11)
- ADVAXIS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Thu, Mar 7)
- Advaxis to Provide 2013 Business Outlook Call scheduled for 5:00 pm ET todayCCBN(Wed, Mar 6)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Oct-13)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Advaxis, Inc., a clinical development stage biotechnology company, engages in the development of immunotherapies for cancer and infectious diseases. The companys platform technology generates an immune response by serving as its own adjuvant...
View More